trientine has been researched along with Neoplasms in 5 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most common cancers were head and neck (n = 13), non-small cell lung (n = 10) and epithelial ovarian (n = 8)." | 2.79 | Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. ( Falchook, G; Fu, S; Hong, D; Hou, MM; Janku, F; Kuo, MT; Kurzrock, R; Naing, A; Piha-Paul, S; Tsimberidou, A; Wheler, J; Zinner, R, 2014) |
| "Treatment of PC-3 prostate cancer cells with the most potent compound led to appreciable cell cycle arrest at a G1/G0 phase and cell apoptosis induction." | 1.43 | Synthesis and evaluation of 1,7-diheteroarylhepta-1,4,6-trien-3-ones as curcumin-based anticancer agents. ( Chen, C; Chen, G; Chen, QH; Wang, G; Wang, R; Zhang, Q; Zhang, X; Zheng, S; Zhong, Q, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, S | 1 |
| Hou, MM | 1 |
| Wheler, J | 1 |
| Hong, D | 1 |
| Naing, A | 1 |
| Tsimberidou, A | 1 |
| Janku, F | 1 |
| Zinner, R | 1 |
| Piha-Paul, S | 1 |
| Falchook, G | 1 |
| Kuo, MT | 1 |
| Kurzrock, R | 1 |
| Wang, R | 1 |
| Zhang, X | 1 |
| Chen, C | 1 |
| Chen, G | 1 |
| Zhong, Q | 1 |
| Zhang, Q | 1 |
| Zheng, S | 1 |
| Wang, G | 1 |
| Chen, QH | 1 |
| Nasulewicz, A | 1 |
| Opolski, A | 1 |
| Sproull, M | 1 |
| Brechbiel, M | 1 |
| Camphausen, K | 1 |
| Brewer, GJ | 1 |
3 reviews available for trientine and Neoplasms
| Article | Year |
|---|---|
[The role of copper in tumor angiogenesis--clinical implications].
Topics: Animals; Captopril; Copper; Humans; Neoplasms; Neovascularization, Pathologic; Oxidation-Reduction; | 2002 |
Antiangiogenic therapy through copper chelation.
Topics: Angiogenesis Inhibitors; Animals; Chelating Agents; Chelation Therapy; Copper; Corneal Neovasculariz | 2003 |
Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Topics: Animals; Copper; Fibrosis; Humans; Inflammation; Molybdenum; Neoplasms; Neovascularization, Patholog | 2005 |
1 trial available for trientine and Neoplasms
| Article | Year |
|---|---|
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Ceruloplasmin; Chelating Agents; Copper; Female; Hu | 2014 |
1 other study available for trientine and Neoplasms
| Article | Year |
|---|---|
Synthesis and evaluation of 1,7-diheteroarylhepta-1,4,6-trien-3-ones as curcumin-based anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Design; Drug Screening A | 2016 |